InvestorsHub Logo
Followers 59
Posts 7440
Boards Moderated 0
Alias Born 10/20/2014

Re: Pharmacydude post# 397562

Tuesday, 01/10/2023 7:41:51 PM

Tuesday, January 10, 2023 7:41:51 PM

Post# of 430137
Pharmacydude, All of us investors want to see shareholder value maximized
and the uptake of Vascepa optimized. My view remains that only a BP owning
AMRN can accomplish this. KM was hired for his expertise on getting approvals
and reimbursements in Europe. Germany was certainly a major disappointment.
If AMRN had been owned by a BP such as Bayer (with deep connections to
Germany) I wonder if the negotiations would have had a different outcome.
AMRN has always lacked the "gravitas" of a BP. Imagine if Pfizer decided
that Vascepa would be a viable treatment for COVID induced CVD. My guess
is that if COVID induced CVD were deemed to be a serious enough problem
they could find a way to get governments to pay for it. My impression is that
KM has no interest in selling the company. I think Denner would actively
solicit the best possible deal for all concerned.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News